Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Lancet has published the results of the Procedural Pain in Premature Infants (Poppi) study, ran by the Paediatric Neuroimaging Group and co-ordinated by the National Perinatal Epidemiology Unit (Clinical Trials Unit).

The year-long study examined the effects of morphine as an analgesic for premature non-ventilated babies undergoing routine eye examinations. Thirty-one infants were enrolled in the trial, and assigned to either morphine or placebo treatment.

The results show that administration of oral morphine to non-ventilated premature infants prior to retinopathy of prematurity screening has the potential for harm without suggestion of analgesic efficacy. Difficulties in measuring infant pain are widely recognised, and the methodology used to measure both analgesic efficacy and side effects of a pharmacological intervention in the Poppi trial sets new standards for the conduct of clinical trials of analgesics in infants.

Completing the Poppi trial has been a fantastic achievement. The project has bought together people from many disciplines who want to improve the treatment of pain in prematurely-born infants. We are very excited about the next phase of our work where we will use the methodology developed in the Poppi trial to test the analgesic efficacy and safety of other pharmacological interventions.

 

 - said Professor Rebeccah Slater, head of Paediatric Neuroimaging.

 

 

 

 

 

 

 

 

 

For an overview of the procedure and results of the study, watch our animation:

 

or read an overview on the NPEU website.

 

The journal article can be found here: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial

and you can read our comment in Lancet Child and Adolescent here: A universal right to pain relief: balancing the risks in a vulnerable patient population.

Similar stories

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

COVID-19 Research Vaccinology

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

COVID-19 Research Vaccinology

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Clinical Trials Vaccinology

The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Children’s pain ‘swept under the carpet for too long’ – Lancet Commission

Neuroimaging Publication Research

The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

COVID-19 Clinical Trials Vaccinology

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.

Oxford COVID-19 vaccine to begin phase II/III human trials

COVID-19 Clinical Trials Vaccinology

Oxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.